GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Luoxin Pharmaceutical Group Stock Co Ltd (OTCPK:SLUXY) » Definitions » Change In Other Working Capital

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Change In Other Working Capital : $0.0 Mil (TTM As of Mar. 2017)


View and export this data going back to 2009. Start your Free Trial

What is Shandong Luoxin Pharmaceutical Group Stock Co Change In Other Working Capital?

Shandong Luoxin Pharmaceutical Group Stock Co's Change In Other Working Capital for the quarter that ended in Mar. 2017 was $0.0 Mil. It means Shandong Luoxin Pharmaceutical Group Stock Co's Other Working Capital stayed the same from Dec. 2016 to Mar. 2017 .

Shandong Luoxin Pharmaceutical Group Stock Co's Change In Other Working Capital for the fiscal year that ended in Dec. 2016 was $73.1 Mil. It means Shandong Luoxin Pharmaceutical Group Stock Co's Other Working Capital increased by $73.1 Mil from Dec. 2015 to Dec. 2016 .


Shandong Luoxin Pharmaceutical Group Stock Co Change In Other Working Capital Historical Data

The historical data trend for Shandong Luoxin Pharmaceutical Group Stock Co's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Luoxin Pharmaceutical Group Stock Co Change In Other Working Capital Chart

Shandong Luoxin Pharmaceutical Group Stock Co Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.11 18.52 27.53 35.41 73.07

Shandong Luoxin Pharmaceutical Group Stock Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shandong Luoxin Pharmaceutical Group Stock Co Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Luoxin Pharmaceutical Group Stock Co Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Shandong Luoxin Pharmaceutical Group Stock Co's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Business Description

Traded in Other Exchanges
N/A
Address
Shandong Luoxin Pharmaceutical Group Stock Co Ltd along with its subsidiaries is engaged in the manufacturing and selling of pharmaceutical products. It is involved in the research and development of LXI-15028, a potassium-competitive acid blocker, which is in phase III development for the treatment of reflux esophagitis and other acid-related gastrointestinal diseases; and LXI-15029, an ATP mTOR kinase inhibitor that acts as potent and selective dual inhibitors of mTORC1 and mTORC2 that controls the process of tumor formation and growth. The company mainly operates in the People's Republic of China.

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Headlines

No Headlines